AMEX delisting sends Avitar to OTCBB:
This article was originally published in Clinica
The American Stock Exchange (AMEX) has struck oral fluid diagnostic developer Avitar off its trading list, after the company failed to comply with the exchange's listing standards. The Canton, Massachusetts firm, which has been suffering net losses over the last five years, said it will be quoted on the Pink Sheets until its stock is listed on the OTC Bulletin Board.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.